News & analysis on the clinical development and manufacture of large molecule drugs
CGT Catapult, Sharon Brownlow
By Ben Hargreaves
- Last updated on
The UK’s Cell and Gene Therapy Catapult (CGT Catapult) confirmed the promotion of Sharon Brownlow to the position of chief business officer, after the previous incumbent moved into the position of CEO.
Brownlow will begin her new role on August 1, moving from her prior position of commercial director within the company. In the role, she will be responsible for business strategy and ensuring that the funding is coming into the project.
According CGT Catapult, Brownlow had played a ‘pivotal role’ in securing collaborative research funding to support the growth and productivity of its manufacturing center.
Before joining the CGT Catapult three and a half years ago, Brownlow had been a business development manager at Cobra Biologics for five years, and UK sales and marketing manager for Applikon Biotechnology, again for five years.